ImpediMed logo

IPD - ImpediMed Share Price

A$0.12 0.0  0.0%

Last Trade - 7:10am

Small Cap
Market Cap £71.6m
Enterprise Value £61.5m
Revenue £3.60m
Position in Universe 774th / 1911
Unlock IPD Revenue
Relative Strength (%)
1m -15.5%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
4.93 5.95 6.13 3.32 4.16 5.74 10.1 20.8 +3.1%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ImpedimedLimited revenues increased 26% to A$3.6M. Net lossdecreased 19% to A$10.4M. Revenues reflect Australiasegment increase of 16% to A$548K. Lower net loss reflectsResearch and Clinical Trials decrease of 59% to A$819K(expense), Travel Expenses decrease of 88% to A$67K(expense). Basic Earnings per Share excluding ExtraordinaryItems increased from -A$0.03 to -A$0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IPD Revenue Unlock IPD Revenue

Net Income

IPD Net Income Unlock IPD Revenue

Normalised EPS

IPD Normalised EPS Unlock IPD Revenue

PE Ratio Range

IPD PE Ratio Range Unlock IPD Revenue

Dividend Yield Range

IPD Dividend Yield Range Unlock IPD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
IPD EPS Forecasts Unlock IPD Revenue
Profile Summary

ImpediMed Limited is an Australia-based company, which is a global provider of medical technology to measure, monitor and manage fluid status and body composition. The principal activities of the Company consist of the development, manufacture and sale of bioimpedance instruments and consumables, and the sale of electronic test and measurement devices. The Company's operating segments include Medical, and Test & Measurement. The Medical segment is a supplier of non-invasive medical devices to over two underserved markets: aiding in the subclinical assessment of individuals at risk of secondary lymphedema, and the monitoring of body composition and hydration. The medical cash-generating unit (CGU) is the core business of the Company. The Test & Measurement segment is a supplier of power precision testing and measuring equipment (T&M). The Company's geographical locations include Australia/rest of world (ROW) and North America.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated September 27, 1999
Public Since October 24, 2007
No. of Shareholders: 4,144
No. of Employees: 69
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange Australian Stock Exchange - SEATS
Shares in Issue 1,076,596,070
Free Float (0.0%)
Eligible for
IPD Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IPD
Upcoming Events for IPD
Wednesday 27th October, 2021 Estimate
ImpediMed Ltd Annual Shareholders Meeting
Frequently Asked Questions for ImpediMed
What is the ImpediMed share price?

As of 7:10am, shares in ImpediMed are trading at A$0.12, giving the company a market capitalisation of £71.6m. This share price information is delayed by 15 minutes.

How has the ImpediMed share price performed this year?

Shares in ImpediMed are currently trading at A$0.12 and the price has moved by 0.186k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ImpediMed price has moved by 0.117k% over the past year.

What are the analyst and broker recommendations for ImpediMed?

Of the analysts with advisory recommendations for ImpediMed, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ImpediMed is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will ImpediMed next release its financial results?

ImpediMed is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the ImpediMed dividend yield?

ImpediMed does not currently pay a dividend.

Does ImpediMed pay a dividend?

ImpediMed does not currently pay a dividend.

When does ImpediMed next pay dividends?

ImpediMed does not currently pay a dividend.

How do I buy ImpediMed shares?

To buy shares in ImpediMed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ImpediMed?

Shares in ImpediMed are currently trading at A$0.12, giving the company a market capitalisation of £71.6m.

Where are ImpediMed shares listed? Where are ImpediMed shares listed?

Here are the trading details for ImpediMed:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: IPD
What kind of share is ImpediMed?

Based on an overall assessment of its quality, value and momentum, ImpediMed is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ImpediMed share price forecast 2021?

Shares in ImpediMed are currently priced at A$0.12. At that level they are trading at 46.67% discount to the analyst consensus target price of 0.00.

Analysts covering ImpediMed currently have a consensus Earnings Per Share (EPS) forecast of -0.018 for the next financial year.

How can I tell whether the ImpediMed share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ImpediMed. Over the past six months, the relative strength of its shares against the market has been 16.5%. At the current price of A$0.12, shares in ImpediMed are trading at 12.49% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ImpediMed PE Ratio?

We were not able to find PE ratio data for ImpediMed.

Who are the key directors of ImpediMed?

ImpediMed's management team is headed by:

Dennis Schlaht - SVP
Catherine Kingsford - SVP
Richard Carreon - CEO
Scott Ward - NEC
David Adams - SVP
Frank Vicini - OTH
Leanne Ralph - SEC
Amit Patel - NID
Judith Downes - NID
Robert Graham - NID
Shashi Tripathi - CTO
Timothy Cruickshank - CFO
David Anderson - NID
Michael Bassett - SVP
Nancy Deisinger - VPR
Who are the major shareholders of ImpediMed?

Here are the top five shareholders of ImpediMed based on the size of their shareholding:

Allan Gray Australia Pty Ltd Investment Advisor
Percentage owned: 9.91% (147.8m shares)
Paradice Investment Management Pty. Ltd. Investment Advisor
Percentage owned: 6.9% (102.9m shares)
Australian Ethical Investment Ltd. Investment Advisor
Percentage owned: 5.81% (86.6m shares)
Brown (Gregory Wayne) Individual Investor
Percentage owned: 2.22% (33.1m shares)
Sunlora Pty. Ltd. Corporation
Percentage owned: 0.94% (14.0m shares)
Similar to IPD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.